Publication Name	World Journal of Clinical Cases
Manuscript ID	108181
Country	Egypt

Received	2025-04-09 00:51
Peer-Review Started	2025-04-09 00:51
To Make the First Decision
Return for Revision	2025-05-15 00:26
Revised	2025-05-18 16:32
Second Decision	2025-07-07 02:43
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-07-07 08:39
Articles in Press	2025-07-07 08:39
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-08-01 04:15
Publish the Manuscript Online	2025-08-07 07:38

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Field of Vision
Article Title	Kelleni’s protocol incorporating non-steroidal anti-inflammatory drugs and nitazoxanide to early manage dengue virus disease: An antiviral silver bullet
Manuscript Source	Invited Manuscript
All Author List	Mina Thabet Kelleni
Funding Agency and Grant Number
Corresponding Author	Mina Thabet Kelleni, Assistant Professor, MD, PhD, Department of Pharmacology, College of Medicine, Minia University, Main Road Shalaby Land, Minya 61519, Egypt. mina.kelleni@mu.edu.eg
Key Words	COVID-19; Dengue; Influenza; Kelleni’s protocol; Norovirus; SARS-CoV-2; Respiratory syncytial virus
Core Tip	Dengue virus disease (DVD) is estimated to affect up to 400 million people globally every year. The World Health Organization considers it the fastest growing mosquito-borne infection, and recently the infection has surpassed its historic transmission area. Unfortunately, there is no approved specific antiviral therapy to manage it. In this article, we argue that non-steroidal anti-inflammatory drugs and Kelleni's antiviral protocol could be easily repurposed to manage early DVD and prevent its progression to dengue hemorrhagic fever and death, as it has done with severe acute respiratory syndrome coronavirus 2 and other viruses. Kelleni's protocol has proven to be life-saving for patients of all ages in real-world practice, and it could be seen as an ideal empiric broad-spectrum antiviral Holy Grail that is much needed in our clinical practice.
Publish Date	2025-08-07 07:38
Citation	<p>Kelleni MT. Kelleni’s protocol incorporating non-steroidal anti-inflammatory drugs and nitazoxanide to early manage dengue virus disease: An antiviral silver bullet. <i>World J Clin Cases</i> 2025; 13(28): 108181</p>
URL	https://www.wjgnet.com/2307-8960/full/v13/i28/108181.htm
DOI	https://dx.doi.org/10.12998/wjcc.v13.i28.108181

Full Article (PDF)	WJCC-13-108181-with-cover.pdf
Manuscript File	108181_Auto_Edited_072910.docx
Answering Reviewers	108181-answering-reviewers.pdf
Audio Core Tip	108181-audio.m4a
Conflict-of-Interest Disclosure Form	108181-conflict-of-interest-statement.pdf
Copyright License Agreement	108181-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	108181-non-native-speakers.pdf
Peer-review Report	108181-peer-reviews.pdf
Scientific Misconduct Check	108181-scientific-misconduct-check.png
Scientific Editor Work List	108181-scientific-editor-work-list.pdf
CrossCheck Report	108181-crosscheck-report.pdf